Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 7/20 | 0.36 |
| ▸ | ACHE | P22303 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 2/20 | 0.35 |
| ▸ | CCND1 | P24385 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924683 | 0.89 | MAPT (0.38) | POLB | |
| SCHEMBL2916830 | 0.89 | MEN1 (0.33) | POLB | |
| SCHEMBL2923072 | 0.88 | TP53 (0.35) | — | |
| SCHEMBL2922473 | 0.86 | TMEM97 (0.35) | — | |
| SCHEMBL2925215 | 0.84 | TP53 (0.37) | — | |
| SCHEMBL2921748 | 0.84 | TMEM97 (0.34) | — | |
| SCHEMBL8144287 | 0.84 | MAPT (0.36) | POLB | |
| SCHEMBL8147430 | 0.84 | MAPT (0.36) | POLB | |
| SCHEMBL2920641 | 0.83 | DRD2 (0.36) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8139374 | 0.83 | MAPT (0.35) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | POLB 2217/4885NPC1 1614/4885RAB9A 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.